Which of the following is a characteristic of 99mTc lidofenin?

The choice indicating that 99mTc lidofenin is never prepared with reduced 99mTc pertechnetate is correct because 99mTc lidofenin is a radiopharmaceutical that is specifically formulated for imaging in hepatobiliary studies and not derived from reduced forms of technetium. The preparation of this radiopharmaceutical involves the use of 99mTc that is in its pertechnetate form, which contains technetium in the +7 oxidation state, allowing it to maintain its stability and ideal characteristics for imaging.

In the context of the other options, the use of 99mTc lidofenin primarily lies outside of thyroid imaging, as its application is targeted towards evaluating liver function and biliary tree disorders, not the thyroid. Concerning its use in perfusion studies, lidofenin is not among the commonly employed agents for cardiac perfusion, as other tracers such as 99mTc-sestamibi or 99mTc-tetrofosmin are more typical. Finally, while 99mTc does have a short half-life of approximately 6 hours, 99mTc lidofenin itself does not specifically characterize its half-life, as the focus is more on the pharmacok